{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T22:16:24Z","timestamp":1784758584176,"version":"3.55.0"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004921","name":"Shanghai Jiao Tong University","doi-asserted-by":"publisher","award":["AF1700037"],"award-info":[{"award-number":["AF1700037"]}],"id":[{"id":"10.13039\/501100004921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004921","name":"Shanghai Jiao Tong University","doi-asserted-by":"publisher","award":["WF220217002"],"award-info":[{"award-number":["WF220217002"]}],"id":[{"id":"10.13039\/501100004921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.bioorg.2021.104815","type":"journal-article","created":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T19:18:22Z","timestamp":1615403902000},"page":"104815","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["The ups, downs and new trends of IDO1 inhibitors"],"prefix":"10.1016","volume":"110","author":[{"given":"Shulun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.bioorg.2021.104815_b0005","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrd3500","article-title":"Cancer immunotherapy\u2013revisited","volume":"10","author":"Lesterhuis","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.bioorg.2021.104815_b0010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"19","key":"10.1016\/j.bioorg.2021.104815_b0015","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"New Engl.\u00a0 J. Med."},{"issue":"19","key":"10.1016\/j.bioorg.2021.104815_b0020","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"New Engl.\u00a0 J. Med."},{"issue":"19","key":"10.1016\/j.bioorg.2021.104815_b0025","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"New Engl.\u00a0 J. Med."},{"key":"10.1016\/j.bioorg.2021.104815_b0030","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/bs.ai.2015.12.005","article-title":"Combinatorial Cancer Immunotherapies","volume":"130","author":"Hellmann","year":"2016","journal-title":"Adv. Immunol."},{"issue":"3","key":"10.1016\/j.bioorg.2021.104815_b0035","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.bioorg.2021.104815_b0040","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-018-0582-8","article-title":"Next generation of immune checkpoint therapy in cancer: new developments and challenges","volume":"11","author":"Marin-Acevedo","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2021.104815_b0045","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3389\/fimmu.2019.00453","article-title":"Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma","volume":"10","author":"Khair","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2021.104815_b0050","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3389\/fimmu.2020.01185","article-title":"Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies,","volume":"11","author":"Zhai","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2021.104815_b0055","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.3389\/fimmu.2018.01879","article-title":"What May Constrain the Success of Indoleamine 2,3-Dioxygenase 1 Inhibitors in Cancer Immunotherapy?","volume":"9","author":"Eleftheriadis","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2021.104815_b0060","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3389\/fonc.2018.00423","article-title":"Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers","volume":"8","author":"Komiya","year":"2018","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.bioorg.2021.104815_b0065","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.bioorg.2021.104815_b0070","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41568-019-0106-z","article-title":"Immune control by amino acid catabolism during tumorigenesis and therapy","volume":"19","author":"Lemos","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.bioorg.2021.104815_b0075","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.tips.2012.09.006","article-title":"An expanding range of targets for kynurenine metabolites of tryptophan","volume":"34","author":"Stone","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bioorg.2021.104815_b0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fimmu.2015.00034","article-title":"Tryptophan-degrading enzymes in tumoral immune resistance","volume":"6","author":"van Baren","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2021.104815_b0085","first-page":"673","article-title":"Cancer Immunotherapy by Targeting IDO1\/TDO and Their Downstream Effectors","volume":"5","author":"Platten","year":"2014","journal-title":"Front. Immunol."},{"issue":"24","key":"10.1016\/j.bioorg.2021.104815_b0090","doi-asserted-by":"crossref","first-page":"9421","DOI":"10.1021\/acs.jmedchem.5b00326","article-title":"Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors","volume":"58","author":"Rohrig","year":"2015","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2021.104815_b0095","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1158\/2326-6066.CIR-14-0137","article-title":"Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues","volume":"3","author":"Theate","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"22","key":"10.1016\/j.bioorg.2021.104815_b0100","doi-asserted-by":"crossref","first-page":"6985","DOI":"10.1158\/1078-0432.CCR-11-1331","article-title":"Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives","volume":"17","author":"Godin-Ethier","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2021.104815_b0105","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2051-1426-2-21","article-title":"The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma","volume":"2","author":"Li","year":"2014","journal-title":"J. ImmunoTher. Cancer"},{"issue":"5","key":"10.1016\/j.bioorg.2021.104815_b0110","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","article-title":"Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond","volume":"18","author":"Platten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.bioorg.2021.104815_b0115","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1073\/pnas.1113873109","article-title":"Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase","volume":"109","author":"Pilotte","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.bioorg.2021.104815_b0120","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.immuni.2005.03.013","article-title":"GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase","volume":"22","author":"Munn","year":"2005","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.bioorg.2021.104815_b0125","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.4161\/onci.21716","article-title":"IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan","volume":"1","author":"Metz","year":"2012","journal-title":"Oncoimmunology"},{"issue":"5","key":"10.1016\/j.bioorg.2021.104815_b0130","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3892\/ijmm.2016.2547","article-title":"Differential effects of the two amino acid sensing systems, the GCN2 kinase and the mTOR complex 1, on primary human alloreactive CD4(+) T-cells","volume":"37","author":"Eleftheriadis","year":"2016","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.bioorg.2021.104815_b0135","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1146\/annurev-immunol-020711-075024","article-title":"Regulation of immune responses by mTOR","volume":"30","author":"Powell","year":"2012","journal-title":"Annu. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.bioorg.2021.104815_b0140","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.smim.2011.01.008","article-title":"External influences on the immune system via activation of the aryl hydrocarbon receptor","volume":"23","author":"Stockinger","year":"2011","journal-title":"Semin. Immunol."},{"issue":"3","key":"10.1016\/j.bioorg.2021.104815_b0145","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.it.2012.10.001","article-title":"Indoleamine 2,3 dioxygenase and metabolic control of immune responses","volume":"34","author":"Munn","year":"2013","journal-title":"Trends Immunol."},{"issue":"5","key":"10.1016\/j.bioorg.2021.104815_b0150","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1124\/mol.116.105361","article-title":"An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER-\/PR-\/Her2- Human Breast Cancer Cells","volume":"90","author":"Novikov","year":"2016","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.bioorg.2021.104815_b0155","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/toxsci\/kfq024","article-title":"Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling","volume":"115","author":"DiNatale","year":"2010","journal-title":"Toxicol. Sci."},{"issue":"2","key":"10.1016\/j.bioorg.2021.104815_b0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087877","article-title":"Identification of cinnabarinic acid as a novel endogenous aryl hydrocarbon receptor ligand that drives IL-22 production","volume":"9","author":"Lowe","year":"2014","journal-title":"PLoS ONE"},{"issue":"24","key":"10.1016\/j.bioorg.2021.104815_b0165","doi-asserted-by":"crossref","first-page":"6795","DOI":"10.1158\/0008-5472.CAN-17-2285","article-title":"Discovery of IDO1 Inhibitors: From Bench to Bedside","volume":"77","author":"Prendergast","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2021.104815_b0170","first-page":"1","article-title":"Preliminary safety and efficacy data from a phase 1\/2 study of epacadostat (INCB024360) in combination with pembrolizumab in patients with advanced\/metastatic melanoma","volume":"14","author":"Gajewski","year":"2016","journal-title":"J. Transl. Med."},{"issue":"6389","key":"10.1016\/j.bioorg.2021.104815_b0175","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1126\/science.360.6389.588","article-title":"A new cancer immunotherapy suffers a setback","volume":"360","author":"Garber","year":"2018","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bioorg.2021.104815_b0180","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00281-018-0702-0","article-title":"Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond","volume":"41","author":"Muller","year":"2019","journal-title":"Semin. Immunopathol."},{"issue":"10","key":"10.1016\/j.bioorg.2021.104815_b0185","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1039\/C9MD00208A","article-title":"Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors","volume":"10","author":"Wang","year":"2019","journal-title":"Medchemcomm"},{"issue":"8","key":"10.1016\/j.bioorg.2021.104815_b0190","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1470-2045(19)30312-2","article-title":"Echoes of a failure: what lessons can we learn?","volume":"20","author":"Sondak","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bioorg.2021.104815_b0195","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/bs.ircmb.2017.07.004","article-title":"Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer","volume":"336","author":"Prendergast","year":"2018","journal-title":"Int Rev Cell Mol Biol"},{"issue":"13 Supplement","key":"10.1016\/j.bioorg.2021.104815_b0200","article-title":"Abstract CT116: BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1\/2a trial","volume":"77","author":"Siu","year":"2017","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bioorg.2021.104815_b0205","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1124\/dmd.116.074609","article-title":"In Vitro Interactions of Epacadostat and its Major Metabolites with Human Efflux and Uptake Transporters: Implications for Pharmacokinetics and Drug Interactions","volume":"45","author":"Zhang","year":"2017","journal-title":"Drug Metab. Dispos."},{"issue":"7","key":"10.1016\/j.bioorg.2021.104815_b0210","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11912-018-0697-7","article-title":"Combination Immunotherapy in Non-small Cell Lung Cancer","volume":"20","author":"Marmarelis","year":"2018","journal-title":"Curr. Oncol. Rep."},{"issue":"3","key":"10.1016\/j.bioorg.2021.104815_b0215","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nm1196","article-title":"Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy","volume":"11","author":"Muller","year":"2005","journal-title":"Nat. Med."},{"issue":"15","key":"10.1016\/j.bioorg.2021.104815_b0220","first-page":"1","article-title":"Preliminary results from a phase 1\/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma","volume":"32","author":"Gibney","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bioorg.2021.104815_b0225","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1158\/0008-5472.CAN-15-1456","article-title":"STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation","volume":"76","author":"Lemos","year":"2016","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.bioorg.2021.104815_b0230","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1021\/acsmedchemlett.6b00391","article-title":"INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology","volume":"8","author":"Yue","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.bioorg.2021.104815_b0235","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/13543776.2018.1441290","article-title":"A patent review of IDO1 inhibitors for cancer","volume":"28","author":"Cheong","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"issue":"18","key":"10.1016\/j.bioorg.2021.104815_b0240","doi-asserted-by":"crossref","first-page":"8136","DOI":"10.18632\/oncotarget.2357","article-title":"A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors","volume":"5","author":"Soliman","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2021.104815_b0245","series-title":"Tumor therapy comprising an antibody against a tumor antigen in combination with an IDO inhibitor","first-page":"151","author":"Tokunaga","year":"2017"},{"issue":"1","key":"10.1016\/j.bioorg.2021.104815_b0250","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40425-018-0351-9","article-title":"Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors","volume":"6","author":"Nayak-Kapoor","year":"2018","journal-title":"J. ImmunoTher. Cancer"},{"issue":"19 Supplement","key":"10.1016\/j.bioorg.2021.104815_b0255","article-title":"Abstract 5023: Synergistic antitumor effects of combinatorial immune checkpoint inhibition with anti-PD-1\/PD-L antibodies and the IDO pathway inhibitors NLG-919 and indoximod in the context of active immunotherapy","volume":"74","author":"Mautino","year":"2014","journal-title":"Cancer Res."},{"issue":"14","key":"10.1016\/j.bioorg.2021.104815_b0260","doi-asserted-by":"crossref","first-page":"6705","DOI":"10.1021\/acs.jmedchem.9b00662","article-title":"Discovery of Clinical Candidate (1R,4r)-4-((R)-2-((S)-6-Fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl)cyc lohexan-1-ol (Navoximod), a Potent and Selective Inhibitor of Indoleamine 2,3-Dioxygenase 1","volume":"62","author":"Kumar","year":"2019","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2021.104815_b0265","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1073\/pnas.0508996103","article-title":"Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase","volume":"103","author":"Sugimoto","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"16","key":"10.1016\/j.bioorg.2021.104815_b0270","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1021\/jm800512z","article-title":"Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase","volume":"51","author":"Kumar","year":"2008","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.bioorg.2021.104815_b0275","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.2174\/092986712801323180","article-title":"Modulation of cytochrome-P450 inhibition (CYP) in drug discovery: a medicinal chemistry perspective","volume":"19","author":"Kumar","year":"2012","journal-title":"Curr. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2021.104815_b0280","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1021\/acsmedchemlett.9b00114","article-title":"Discovery of Imidazoisoindole Derivatives as Highly Potent and Orally Active Indoleamine-2,3-dioxygenase Inhibitors","volume":"10","author":"Tu","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.bioorg.2021.104815_b0285","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1021\/acsmedchemlett.0c00004","article-title":"Implementation of the CYP Index for the Design of Selective Tryptophan-2,3-dioxygenase Inhibitors","volume":"11","author":"Parr","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"21","key":"10.1016\/j.bioorg.2021.104815_b0290","doi-asserted-by":"crossref","first-page":"8321","DOI":"10.1021\/jm401195n","article-title":"Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice","volume":"56","author":"Yang","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.104815_b0295","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejmech.2016.07.013","article-title":"Establishment of a human indoleamine 2, 3-dioxygenase 2 (hIDO2) bioassay system and discovery of tryptanthrin derivatives as potent hIDO2 inhibitors","volume":"123","author":"Li","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.104815_b0300","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejmech.2018.10.017","article-title":"Tryptophan 2,3-dioxygenase inhibitory activities of tryptanthrin derivatives","volume":"160","author":"Zhang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"20","key":"10.1016\/j.bioorg.2021.104815_b0305","doi-asserted-by":"crossref","first-page":"9161","DOI":"10.1021\/acs.jmedchem.9b01079","article-title":"N-Benzyl\/Aryl Substituted Tryptanthrin as Dual Inhibitors of Indoleamine 2,3-Dioxygenase and Tryptophan 2,3-Dioxygenase","volume":"62","author":"Yang","year":"2019","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.bioorg.2021.104815_b0310","doi-asserted-by":"crossref","first-page":"9617","DOI":"10.1021\/acs.jmedchem.7b00974","article-title":"Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271\/PF-06840003) and Its Characterization as a Potential Clinical Candidate","volume":"60","author":"Crosignani","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.104815_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111985","article-title":"Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as IDO1\/TDO dual inhibitors","volume":"188","author":"Cui","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.104815_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112703","article-title":"Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO)","volume":"207","author":"Pan","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"23","key":"10.1016\/j.bioorg.2021.104815_b0325","doi-asserted-by":"crossref","first-page":"6194","DOI":"10.1016\/j.bmc.2016.10.003","article-title":"Discovery and preliminary structure-activity relationship of 1H-indazoles with promising indoleamine-2,3-dioxygenase 1 (IDO1) inhibition properties","volume":"24","author":"Qian","year":"2016","journal-title":"Bioorg. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2021.104815_b0330","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.bmc.2019.02.014","article-title":"4,6-Substituted-1H-Indazoles as potent IDO1\/TDO dual inhibitors","volume":"27","author":"Yang","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.104815_b0335","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.3389\/fimmu.2020.01861","article-title":"Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses","volume":"11","author":"Merlo","year":"2020","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bioorg.2021.104815_b0340","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/intimm\/dxz003","article-title":"IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation","volume":"31","author":"Metz","year":"2019","journal-title":"Int. Immunol."},{"key":"10.1016\/j.bioorg.2021.104815_bib556","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111629","article-title":"Discovery of phosphonamidate IDO1 inhibitors for the treatment of non-small cell lung cancer","volume":"182","author":"Du","year":"2019","journal-title":"Eur. J. Med. Chem"},{"key":"10.1016\/j.bioorg.2021.104815_b0345","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ejmech.2018.11.010","article-title":"Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase","volume":"162","author":"Winters","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2021.104815_b0350","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41467-017-01725-8","article-title":"Structural insights into substrate and inhibitor binding sites in human indoleamine 2,3-dioxygenase 1","volume":"8","author":"Lewis-Ballester","year":"2017","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.bioorg.2021.104815_b0355","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1021\/ml500247w","article-title":"Crystal Structures and Structure-Activity Relationships of Imidazothiazole Derivatives as IDO1 Inhibitors","volume":"5","author":"Tojo","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"issue":"36","key":"10.1016\/j.bioorg.2021.104815_b0360","doi-asserted-by":"crossref","first-page":"12866","DOI":"10.1021\/ja9029768","article-title":"Inhibitory substrate binding site of human indoleamine 2,3-dioxygenase","volume":"131","author":"Lu","year":"2009","journal-title":"J. Am. Chem. Soc."},{"issue":"19","key":"10.1016\/j.bioorg.2021.104815_b0365","doi-asserted-by":"crossref","first-page":"8784","DOI":"10.1021\/acs.jmedchem.9b00942","article-title":"Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1)","volume":"62","author":"R\u00f6hrig","year":"2019","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.bioorg.2021.104815_b0370","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1073\/pnas.1719190115","article-title":"Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form","volume":"115","author":"Nelp","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.bioorg.2021.104815_b0375","first-page":"1","article-title":"Phase I\/II trial of BMS-986205 and nivolumab as first-line therapy in hepatocellular carcinoma","volume":"37","author":"Chen","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"44","key":"10.1016\/j.bioorg.2021.104815_b0380","doi-asserted-by":"crossref","first-page":"14538","DOI":"10.1021\/jacs.8b07994","article-title":"Mapping the Binding Trajectory of a Suicide Inhibitor in Human Indoleamine 2,3-Dioxygenase 1","volume":"140","author":"Pham","year":"2018","journal-title":"J. Am. Chem. Soc."},{"issue":"3","key":"10.1016\/j.bioorg.2021.104815_b0385","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/cbic.202000298","article-title":"Characterization of Apo-Form Selective Inhibition of Indoleamine 2,3-Dioxygenase*","volume":"22","author":"Ortiz-Meoz","year":"2021","journal-title":"ChemBioChem"},{"issue":"4","key":"10.1016\/j.bioorg.2021.104815_b0390","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1021\/acsmedchemlett.0c00010","article-title":"Strategic Incorporation of Polarity in Heme-Displacing Inhibitors of Indoleamine-2,3-dioxygenase-1 (IDO1)","volume":"11","author":"White","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"7","key":"10.1016\/j.bioorg.2021.104815_b0395","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1021\/acs.jmedchem.9b01799","article-title":"DNA-Encoded Library Technology-Based Discovery, Lead Optimization, and Prodrug Strategy toward Structurally Unique Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors","volume":"63","author":"Kazmierski","year":"2020","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2021.104815_b0400","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","article-title":"Targeted protein degradation: expanding the toolbox","volume":"18","author":"Schapira","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.bioorg.2021.104815_b0405","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1021\/acs.jmedchem.7b01272","article-title":"Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?","volume":"61","author":"Churcher","year":"2018","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.bioorg.2021.104815_b0410","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.2174\/1568026618666181010101922","article-title":"Proteolysis Targeting Chimera (PROTAC): A Paradigm-Shifting Approach in Small Molecule Drug Discovery","volume":"18","author":"Wang","year":"2018","journal-title":"Curr. Top. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2021.104815_b0415","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.bioorg.2021.104815_b0420","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1021\/acschembio.6b01068","article-title":"Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy","volume":"12","author":"Ottis","year":"2017","journal-title":"ACS Chem. Biol."},{"issue":"8","key":"10.1016\/j.bioorg.2021.104815_b0425","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.chembiol.2020.07.020","article-title":"PROTACs: An Emerging Therapeutic Modality in Precision Medicine","volume":"27","author":"Nalawansha","year":"2020","journal-title":"Cell Chem. Biol."},{"issue":"2","key":"10.1016\/j.bioorg.2021.104815_b0430","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.apsb.2019.08.001","article-title":"Degradation of proteins by PROTACs and other strategies","volume":"10","author":"Wang","year":"2020","journal-title":"Acta. Pharm. Sin. B"},{"issue":"52","key":"10.1016\/j.bioorg.2021.104815_b0435","doi-asserted-by":"crossref","first-page":"20828","DOI":"10.1073\/pnas.0810278105","article-title":"SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis","volume":"105","author":"Orabona","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10","key":"10.1016\/j.bioorg.2021.104815_b0440","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.apsb.2020.02.010","article-title":"Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1","volume":"10","author":"Hu","year":"2020","journal-title":"Acta. Pharm. Sin. B"},{"issue":"11","key":"10.1016\/j.bioorg.2021.104815_b0445","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1021\/acsmedchemlett.9b00344","article-title":"Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy","volume":"10","author":"Zhang","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"issue":"23","key":"10.1016\/j.bioorg.2021.104815_b0450","doi-asserted-by":"crossref","first-page":"7364","DOI":"10.1021\/jm900518f","article-title":"Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model","volume":"52","author":"Yue","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.104815_b0455","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejmech.2019.06.037","article-title":"Design, synthesis and antitumor study of a series of N-Cyclic sulfamoylaminoethyl substituted 1,2,5-oxadiazol-3-amines as new indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors","volume":"179","author":"Chen","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.104815_b0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112059","article-title":"Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors","volume":"189","author":"Song","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2021.104815_b0465","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1124\/dmd.116.070680","article-title":"Roles of UGT, P450, and Gut Microbiota in the Metabolism of Epacadostat in Humans","volume":"44","author":"Boer","year":"2016","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.bioorg.2021.104815_b0470","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1021\/acs.jmedchem.9b01549","article-title":"Unique Sulfur-Aromatic Interactions Contribute to the Binding of Potent Imidazothiazole Indoleamine 2,3-Dioxygenase Inhibitors","volume":"63","author":"Peng","year":"2020","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2021.104815_b0475","first-page":"1947","article-title":"Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors","volume":"1814","author":"Meininger","year":"2011","journal-title":"BBA"},{"issue":"6","key":"10.1016\/j.bioorg.2021.104815_b0480","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1021\/acs.jmedchem.9b01809","article-title":"Discovery of Highly Potent Benzimidazole Derivatives as Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors: From Structure-Based Virtual Screening to in Vivo Pharmacodynamic Activity","volume":"63","author":"Serafini","year":"2020","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2021.104815_b0485","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.bmcl.2018.01.032","article-title":"A multicomponent approach in the discovery of indoleamine 2,3-dioxygenase 1 inhibitors: Synthesis, biological investigation and docking studies","volume":"28","author":"Griglio","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.bioorg.2021.104815_b0490","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1021\/acs.jmedchem.9b00726","article-title":"Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets","volume":"63","author":"Skok","year":"2020","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.bioorg.2021.104815_b0495","doi-asserted-by":"crossref","first-page":"8977","DOI":"10.1021\/acs.jmedchem.0c00491","article-title":"Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy","volume":"63","author":"Liu","year":"2020","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.bioorg.2021.104815_b0500","doi-asserted-by":"crossref","first-page":"9305","DOI":"10.1021\/acs.jmedchem.6b00438","article-title":"Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective","volume":"59","author":"Carlino","year":"2016","journal-title":"J. Med. Chem."},{"issue":"22","key":"10.1016\/j.bioorg.2021.104815_b0505","doi-asserted-by":"crossref","first-page":"9791","DOI":"10.1021\/acs.jmedchem.8b00185","article-title":"Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics","volume":"61","author":"Jarhad","year":"2018","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.bioorg.2021.104815_b0510","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Bayat Mokhtari","year":"2017","journal-title":"Oncotarget"},{"issue":"47","key":"10.1016\/j.bioorg.2021.104815_b0515","doi-asserted-by":"crossref","first-page":"9992","DOI":"10.1039\/C7OB02529G","article-title":"Discovery of IDO1 and DNA dual targeting antitumor agents","volume":"15","author":"Fang","year":"2017","journal-title":"Org. Biomol. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2021.104815_b0520","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1021\/acsmedchemlett.7b00487","article-title":"Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors","volume":"9","author":"Fang","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.bioorg.2021.104815_b0525","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1021\/acs.jmedchem.9b01386","article-title":"Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-dioxygenase and Signal Transducer and Activator of Transcription 3","volume":"63","author":"Huang","year":"2020","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2021.104815_b0530","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/ni.2077","article-title":"Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells","volume":"12","author":"Pallotta","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bioorg.2021.104815_b0535","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.bcp.2018.10.033","article-title":"Identification of a 2-propanol analogue modulating the non-enzymatic function of indoleamine 2,3-dioxygenase 1","volume":"158","author":"Albini","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"7","key":"10.1016\/j.bioorg.2021.104815_b0540","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1073\/pnas.1918215117","article-title":"Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation","volume":"117","author":"Mondanelli","year":"2020","journal-title":"PNAS"},{"key":"10.1016\/j.bioorg.2021.104815_b0545","article-title":"Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1","author":"Hu","year":"2020","journal-title":"Acta. Pharm. Sin. B"},{"issue":"5","key":"10.1016\/j.bioorg.2021.104815_b0550","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1124\/mol.114.093369","article-title":"In silico identification of an aryl hydrocarbon receptor antagonist with biological activity in vitro and in vivo","volume":"86","author":"Parks","year":"2014","journal-title":"Mol. Pharmacol."},{"issue":"5997","key":"10.1016\/j.bioorg.2021.104815_b0555","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1191536","article-title":"Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells","volume":"329","author":"Boitano","year":"2010","journal-title":"Science"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206821001929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206821001929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:18:55Z","timestamp":1758615535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206821001929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":112,"alternative-id":["S0045206821001929"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.104815","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The ups, downs and new trends of IDO1 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.104815","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104815"}}